ArticleAmerican journal of physiology. Lung cellular and molecular physiology2024
PAI-1 deficiency drives pulmonary vascular smooth muscle remodeling and pulmonary hypertension.
Abstract read
In one paragraph
Article in American journal of physiology. Lung cellular and molecular physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- Paradigm shift: from pulmonary vasodilation to cardiopulmonary dual-track therapy-a comprehensive review of pathophysiology and advances in pulmonary hypertension-associated right heart failure.Respiratory research · 2026Review
- Advances in the Research of Hypoxia-Inducible Factor-1Alpha and Plasminogen Activator Inhibitor-1 in Vascular-Related Diseases.Journal of clinical medicine research · 2026Review
- Immunological coagulation dual axis stratification identifies ultra high-risk phenotypes in systemic sclerosis.Frontiers in immunology · 2026Article
- Sepsis induces the cardiomyocyte apoptosis and cardiac dysfunction through activation of YAP1/Serpine1/caspase-3 pathway.Open medicine (Warsaw, Poland) · 2024Article
Corrections and comments
- Update of
Authors and funding
24 authors.
Tatiana V KudryashovaUniversity of Pittsburgh Heart, Blood, and Vascular Medicine Institute, Pittsburgh, Pennsylvania, United States.ORCID 0000-0002-2843-5554
Sergei V ZaitsevDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States.
Lifeng JiangDepartment of Internal Medicine, University of California, Davis, California, United States.ORCID 0000-0002-0983-4787
Benjamin J BuckleySchool of Chemistry and Molecular Bioscience and Molecular Horizons Institute, University of Wollongong, Wollongong, New South Wales, Australia.
Joshua P McGuckinSchool of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, Pennsylvania, United States.
Dmitry GoncharovDepartment of Internal Medicine, University of California, Davis, California, United States.
Iryna ZhyvyloDepartment of Internal Medicine, University of California, Davis, California, United States.ORCID 0000-0001-8141-363X
Derek LinDepartment of Internal Medicine, University of California, Davis, California, United States.
Geoffrey NewcombDivision of Pulmonary, Critical Care & Sleep Medicine, Department of Internal Medicine, Davis Heart & Lung Research Institute, The Ohio State University, Columbus, Ohio, United States.ORCID 0000-0002-8356-4818
Bryce PiperDivision of Pulmonary, Critical Care & Sleep Medicine, Department of Internal Medicine, Davis Heart & Lung Research Institute, The Ohio State University, Columbus, Ohio, United States.
Srimathi BogamuwaDivision of Pulmonary, Critical Care & Sleep Medicine, Department of Internal Medicine, Davis Heart & Lung Research Institute, The Ohio State University, Columbus, Ohio, United States.
Aisha SaiyedDepartment of Internal Medicine, University of California, Davis, California, United States.
Leyla TeosDepartment of Internal Medicine, University of California, Davis, California, United States.
Andressa PenaUniversity of Pittsburgh Heart, Blood, and Vascular Medicine Institute, Pittsburgh, Pennsylvania, United States.ORCID 0000-0001-7451-8820
Marie RansonSchool of Chemistry and Molecular Bioscience and Molecular Horizons Institute, University of Wollongong, Wollongong, New South Wales, Australia.ORCID 0000-0002-5570-9645
John R GreenlandSchool of Medicine, University of California, San Francisco, California, United States.
Paul J WoltersSchool of Medicine, University of California, San Francisco, California, United States.
Michael J KelsoSchool of Chemistry and Molecular Bioscience and Molecular Horizons Institute, University of Wollongong, Wollongong, New South Wales, Australia.
Mortimer PonczDepartment of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States.
Horace M DeLisserDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States.
Douglas B CinesDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States.
Elena A GoncharovaDepartment of Internal Medicine, University of California, Davis, California, United States.ORCID 0000-0001-7118-6752
Laszlo FarkasDivision of Pulmonary, Critical Care & Sleep Medicine, Department of Internal Medicine, Davis Heart & Lung Research Institute, The Ohio State University, Columbus, Ohio, United States.
Victoria StepanovaDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States.ORCID 0000-0002-9313-5742
Funding
Pulmonary Hypertension Breakthrough InitiativeR24HL123767 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI ALDRED, MICHEALA A, ERZURUM, SERPIL C. · 2014 to 2017
$10.1MNew Mechanistic Insights & Therapeutic Applications of Megakaryocytes/PlateletsR35HL150698 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI Mortimer Poncz · 2020 to 2026
$7.3MRegulation and Function of RAB7 in the pulmonary endotheliumR01HL139881 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Laszlo Farkas · 2019 to 2026
$3.8MHIPPO Signaling in Pulmonary Arterial HypertensionR01HL130261 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GONCHAROVA, ELENA · 2016 to 2023
$3.5MBC-mediated delivery of thromboprophylaxisR01HL159256 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MUZYKANTOV, VLADIMIR R · 2021 to 2024
$2.6MGATA-6 in pulmonary arterial hypertensionR01HL150638 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GONCHAROVA, ELENA, TROJANOWSKA, MARIA · 2020 to 2023
$2.6MLDHA-lactate signaling in pulmonary arterial hypertensionR01HL172488 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Elena Goncharova · 2024 to 2026
$2.0MUrokinase-type plasminogen activator (uPA) in pathogenesis of lymphangioleiomyomatosis (LAM)R01HL141462 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KRYMSKAYA, VERA P, STEPANOVA, VICTORIA · 2019 to 2022
$1.8MHIPK2 signaling in Pulmonary Arterial HypertensionR01HL166932 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Tatiana V Kudryashova · 2023 to 2026
$1.6MCytomegalovirus Immune Responses in Chronic Lung Allograft Dysfunction PathogenesisI01CX002011 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI GREENLAND, JOHN · 2020 to 2025
–Cardiovascular Medical Research and Education Fund (CMREF)CSRD VA I01 CX002011DHAC | National Health and Medical Research Council (NHMRC) APP1181179DOD | USA | MEDCOM | MRDC | U.S. Army Medical Research Acquisition Activity (USAMRAA) TS150032HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL130261HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL139881HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL150638HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL166932HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL172488HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R35HL150698HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) RO1HL141462HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) RO1HL159256LAM Foundation (TheLAMFoundation) LAM0139P07-19NHLBI NIH HHS R01 HL130261NHLBI NIH HHS R01 HL139881NHLBI NIH HHS R01 HL141462NHLBI NIH HHS R01 HL150638NHLBI NIH HHS R01 HL159256NHLBI NIH HHS R01 HL166932NHLBI NIH HHS R01 HL172488NHLBI NIH HHS R24 HL123767NHLBI NIH HHS R35 HL150698ORD | Clinical Science Research and Development (CSRD) CX002011UCSF | Department of Medicine, University of California, San Francisco (UCSF Department of Medicine) Nina Ireland Program for Lung Health
Abstract
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by vasoconstriction and remodeling of small pulmonary arteries (PAs). Central to the remodeling process is a switch of pulmonary vascular cells to a proliferative, apoptosis-resistant phenotype. Plasminogen activator inhibitors-1 and -2 (PAI-1 and PAI-2) are the primary physiological inhibitors of urokinase-type and tissue-type plasminogen activators (uPA and tPA), but their roles in PAH are unsettled. Here, we report that:
Indexed as
Hypertension, PulmonaryMuscle, Smooth, VascularPlasminogen Activator Inhibitor 1Vascular RemodelingAnimalsApoptosisCell ProliferationEndothelial CellsHumansHypertrophy, Right VentricularMaleMechanistic Target of Rapamycin Complex 1MiceMice, Inbred C57BLMice, KnockoutMyocytes, Smooth MuscleMechanistic Target of Rapamycin Complex 1Plasminogen Activator Inhibitor 1Plasminogen Activator Inhibitor 2SERPINE1 protein, humanUrokinase-Type Plasminogen Activatorplasminogen activator inhibitor (PAI-1)pulmonary hypertensionurokinase PA (uPA)
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.